XOMA's (XOMA) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of XOMA (NASDAQ:XOMA - Free Report) in a research note released on Friday morning,Benzinga reports. The brokerage currently has a $104.00 target price on the biotechnology company's stock.

Separately, StockNews.com upgraded shares of XOMA from a "sell" rating to a "hold" rating in a research report on Friday, March 21st.

XOMA Stock Performance

Shares of XOMA stock traded down $0.03 on Friday, hitting $19.91. The stock had a trading volume of 4,820 shares, compared to its average volume of 27,148. The stock has a market cap of $238.44 million, a price-to-earnings ratio of -5.72 and a beta of 1.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a twelve month low of $18.98 and a twelve month high of $35.00. The business's 50 day moving average is $23.63 and its two-hundred day moving average is $26.84.

XOMA (NASDAQ:XOMA - Get Free Report) last posted its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The firm had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million. Analysts forecast that XOMA will post -1.41 EPS for the current year.

Remove Ads

Insider Buying and Selling at XOMA

In other XOMA news, CIO Bradley Sitko acquired 4,134 shares of XOMA stock in a transaction that occurred on Friday, March 21st. The shares were acquired at an average cost of $23.89 per share, with a total value of $98,761.26. Following the completion of the purchase, the executive now directly owns 10,484 shares of the company's stock, valued at $250,462.76. This represents a 65.10 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business's stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The disclosure for this sale can be found here. Insiders own 7.20% of the company's stock.

Institutional Investors Weigh In On XOMA

Several hedge funds and other institutional investors have recently made changes to their positions in XOMA. Geode Capital Management LLC grew its stake in shares of XOMA by 0.6% during the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company's stock worth $4,840,000 after buying an additional 1,138 shares during the last quarter. Woodline Partners LP grew its position in XOMA by 63.9% during the 4th quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company's stock worth $4,107,000 after acquiring an additional 60,927 shares during the last quarter. State Street Corp increased its holdings in XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company's stock worth $3,783,000 after purchasing an additional 1,754 shares in the last quarter. Eversept Partners LP raised its position in XOMA by 1.2% in the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock valued at $2,508,000 after purchasing an additional 1,128 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of XOMA by 1.5% during the fourth quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company's stock valued at $2,396,000 after purchasing an additional 1,340 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.